Skip to main content

Genome-wide, high-resolution detection of copy number, loss of heterozygosity, and genotypes from formalin-fixed, paraffin-embedded tumor tissue using microarrays.

Jacobs S, Thompson ER, Nannya Y, Yamamoto G, Pillai R, Ogawa S, Bailey DK, Campbell IG

Publication: Cancer Res (2007) • Vol 67 • Page 2544-51PMID: 17363572View on PubMed

Purpose

The purpose of this paper was to determine the effects of DNA extraction, preservation method, array type and storage on genotype and loss of heterozygosity (LOH) determination.

Conclusion

The highest yield and the largest Random Amplification of Polymorphic DNA (RAPD)-PCR products were obtained from formalin-fixed paraffin-embedded (FFPE) specimens using phenol-chloroform extraction or a modified QIAgen protocol. The call rate from FFPE specimens was 31.86-86.30 versus 90.07-95.86 from frozen specimens, but the call rates and concordance with frozen specimens could be improved by excluding SNPs on fragments >700 bp from analysis. The authors report that fragment length was a better predictor of array success than specimen age.

Studies (2)

Purpose

The purpose of this study was to determine the effects of DNA extraction method on DNA yield from FFPE ovarian tumors.

Summary of Findings

The highest yield and the largest RAPD-PCR products (800 bp) were obtained using phenol-chloroform extraction or a modified QIAgen protocol. In contrast, use of the Promega, Invitrogen, and Gentra Systems kits produced less consistent results and failed to produce an 800 bp RAPD-PCR product. The DNA yield from the amplification step of the Mapping 50K Xba Assay was 19.2 ug from phenol-chloroform extracted tissue and 21.4 ug with the Qiagen kit.
  • Biospecimens

    TissueOvary
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
    Neoplastic
  • Platforms

    DNASpectrophotometry
    DNARAPD PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Analyte Extraction and PurificationAnalyte isolation method
    ChargeSwitch gDNA Micro Tissue kit (Invitrogen)
    MagneSil Genomic Fixed Tissue System (Promega)
    Modified protocol with DNeasy Tissue kit (Qiagen)
    Phenol-chloroform extraction
    PureGene (Gentra Systems)